Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Cr Cl
Creatinine Clearance |
|
Definition
(140- age) x kg
SCr x 72
(x .85 for females)
|
|
|
Term
|
Definition
|
|
Term
|
Definition
LBF x ER
or
LBF x (Cin-Cout)/Cin
|
|
|
Term
|
Definition
|
|
Term
| First Order Pharmacokinetics |
|
Definition
| Percentage of drug decay over time |
|
|
Term
| Second Order Pharmacokinetics |
|
Definition
| Amount of drug decay over time |
|
|
Term
C
(Concentration of drug on curve) |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Vss
(Volume at Steady State) |
|
Definition
Vc + Vp
Volume in the central and peripheral compartments added together |
|
|
Term
|
Definition
| Fraction of dose that is absorbed relative to IV administration |
|
|
Term
Cmax
(Peak Plasma Concentration) |
|
Definition
highest observed plasma concentration
(depends on rate and extent of absorption) |
|
|
Term
|
Definition
Time of maximum plasma concentration
(depends on rate of absorption only) |
|
|
Term
|
Definition
Area under the curve
(affected by extent of absorption and magnitude of total drug clearance) |
|
|
Term
|
Definition
F= AUCPO/AUCIV
fraction of dose that reaches systemic circulation from non-iv route relative to iv route |
|
|
Term
|
Definition
| Fraction of dose that reaches systemic circulation of one formulation relative to standard formulation |
|
|
Term
|
Definition
The time necessary for plasma concentration to decline by 50% during the elimination phase
(affected by Cl and Vd) |
|
|
Term
|
Definition
| Time necessary to eliminate 50% of the drug from the body after rapid IV injection |
|
|
Term
| Dosing Rate for Oral Drugs |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| binds directly to and activates target |
|
|
Term
|
Definition
| Enhances availability or action of an endogenous ligand/agonist |
|
|
Term
|
Definition
| Reversibly competes with endogenous or exogenous agonist; may overcome by increasing agent |
|
|
Term
| Non-Competitive (Irreversible) Antagonist |
|
Definition
Binds with the active site of the receptor and the maximum response reduced
Cannot be overcome by adding more agonist |
|
|
Term
| Non-Competitive (Allosteric) Antagonist |
|
Definition
Decreases agonist affinity by binding at site distinct from primary agonist
Maximum response reduced |
|
|
Term
|
Definition
| Dose that provides 50% of max response |
|
|
Term
|
Definition
| Plasma concentration that provides 50% of max response |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| High Ionization Decreases Vd |
|
|
Term
|
Definition
| Larger molecules have a lower Vd |
|
|
Term
|
Definition
| High affinity increase Vd |
|
|
Term
|
Definition
Drugs absorbed through GI tract enter portal venous blood to the liver where the CYP450 enzymes in the endoplasmic reticulum of the the hepatocytes break durg down to more polar substances to be excreted
Phase I- oxidation, hydoxalation, demethylation
Phase II- glucuronidation, sulfation, actylation (conjugation reaction) |
|
|
Term
|
Definition
Biliary- feces
Kidneys- Urine
Lungs- breathing off vapors etc. |
|
|
Term
|
Definition
Liver primary site
GI tract, Kidneys, Lungs, plasma esterases |
|
|
